On SpaceX's second-ever earnings call, Elon Musk said both companies formed special committees to explore a combination, with no terms agreed.

Independent director panels will explore a deal between the two companies, with the CEO recused from both.

If the claim holds up, personalized phage therapy could become a new frontline weapon against antibiotic resistance - but proof is far from final.

The consulting giant's strategic review of its Greater China unit could set a benchmark for every multinational weighing its China exposure.

The 2025-26 revenue-sharing figure shows how NIL has turned roster building into a spending game with real financial stakes.